Nucala 100 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FFBY5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $193,183
Award facts
- Contract value 100% obligated
- $193,183.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $193,183.00 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Nucala 100 mg/ml syringes. The contract, issued on January 22, 2026, with an ultimate completion date of January 23, 2026, utilizes firm fixed-price pricing with no set-aside designation, indicating the vendor competed in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499,999,999 contract awarded on November 13, 2025, that positions the company as a critical pharmaceutical supplier for Department of Defense healthcare operations.
The PPV-G GEN V program represents part of a broader $30.3 billion acquisition strategy designed to meet recurring medical supply needs across military healthcare facilities worldwide. Under this master contract structure, DMS Pharmaceutical Group supplies a comprehensive range of pharmaceuticals including branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables. Nucala, an immunosuppressant biologic agent, aligns with the vendor's extensive product portfolio of specialty pharmaceuticals routinely distributed to support Department of Defense medical operations. The company's demonstrated performance across multiple delivery orders reflects its established capability to fulfill the diverse pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FFBY5?
SPE2DR26FFBY5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 22, 2026.
How much is contract SPE2DR26FFBY5 worth?
The government has obligated $193,183 on SPE2DR26FFBY5.
Is contract SPE2DR26FFBY5 an order under another contract?
Yes. SPE2DR26FFBY5 is a delivery order under SPE2DR25D9239, an indefinite delivery contract.
Was contract SPE2DR26FFBY5 competed?
The extent of competition for SPE2DR26FFBY5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award